Background Impaired glomerular function is one of the health problems
Introduction
Due to advances in the treatment of childhood cancer most patients are expected to become long-term survivors. 1, 2 However, the improved prognosis has been accompanied by late, treatment-related complications. As a result, childhood cancer survivors (CCS) are a growing group of individuals who are at risk of premature morbidity and mortality. 3, 4 Nephrotoxicity is one of the late effects identified in CCS presenting either as a decline in glomerular filtration rate (GFR), deterioration of tubular function and/ or proteinuria. It has been suggested that CCS treated with ifosfamide, cisplatin, carboplatin, high-dose (HD-)methotrexate, HD-cyclophosphamide, radiotherapy to the kidney region and/or (partial) nephrectomy are at risk for nephrotoxicity.
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Recently, we showed in a large cross-sectional cohort study including 1442 CCS with a median follow-up of 12 years after diagnosis that 28% had ≥1 renal late effect(s), of whom 62 (4.6%) developed glomerular dysfunction (GFR <90 ml/ min/1.73m 2 ). Higher ifosfamide, cisplatin and carboplatin dose, high-dose (HD-) cyclophosphamide, nephrectomy, and longer follow-up were identified as risk factors for glomerular dysfunction. 18 It is, however, not clear whether CCS will show recovery, deterioration or no change in glomerular function, and what the effects of specific cancer treatments are on the pattern over time. A few smaller cohort studies with limited followup durations have evaluated the change in renal function over time, but results have been inconclusive. 8, 9, 12, 14, 15, 19 Chronic kidney disease may affect quality of life and can lead to premature co-morbidity, such as cardiovascular disease, anaemia, bone disease and malnutrition. 20 To establish adequate follow-up protocols for CCS it is important to know their pattern of glomerular function over time. Therefore, the aim of this study was to investigate time trends and predictors of glomerular function in a large cohort of long-term CCS.
Materials and Methods

Study Population
In 1996, the Late Effects Outpatient Clinic for CCS was established in the Emma
Children's Hospital/Academic Medical Center (EKZ/AMC). Here we offer medical follow-up to CCS for the assessment of late effects. All five-year CCS were identified using the hospital's Childhood Cancer Registry (established in 1966), which contains data on all patients treated for childhood cancer in the EKZ/ AMC regarding diagnosis, treatment and follow-up. All CCS surviving ≥5 years after diagnosis and still alive at the start of the outpatient clinic were invited to participate and were subsequently enrolled into prospective follow-up protocols tailored to previous diagnosis and treatment. To be eligible for this study, patients had to meet the following criteria: 1) diagnosed between January 1966 and January 2003 and treated for a primary malignancy; 2) aged <18 years at diagnosis; 3) treated primarily in the EKZ/AMC; 4) survived ≥5 years after diagnosis.
Follow-Up and Data Collection
All CCS who visited the outpatient clinic between January 1996 and January 2010 received a full medical assessment, consisting of a medical history, physical examination, and additional risk-based diagnostic tests and counselling. CCS were seen at regular intervals (every one, two, or five years), depending on previous cancer treatment and assumed risk for late effects. For example, low-risk childhood cancer survivors (e.g. survivors treated with surgery only)
were invited every five years, while high-risk survivors (e.g. survivors treated with chemotherapy and/or radiotherapy) were invited every year. For each CCS we recorded patient and treatment characteristics, and serum creatinine measurements from each outpatient clinic visit.
The EKZ/AMC institutional review board reviewed and approved the collection of data used for the analyses presented. Written informed consent was obtained from all participants.
Glomerular Function Assessment
To assess glomerular function we measured serum creatinine using an enzymatic IDMS-traceable method (Roche P800, Roche Diagnostics, Almere, the Netherlands). We estimated the GFR using the Schwartz formula for CCS aged ≤18 years with a constant derived by Zappitelli et 
Statistical Analysis
To evaluate the patterns of glomerular function over time we fitted multivariable linear random effects models for GFR as a continuous outcome variable, and multivariable logistic regression models for GFR as a dichotomous outcome variable.
In the random effects models, estimates were obtained via restricted maximum likelihood. In the logistic regression models, estimates were obtained using generalized estimating equations (GEE) with a compound symmetry working correlation matrix. All performed GFR measurements were taken into account.
Follow-up time was included as a continuous predictor variable. The random effects models and GEE adjust for the correlation between repeated observations measured in the same subject and can handle longitudinal data on subjects with varying number of and unequally spaced observations. In all GEE analyses an exchangeable correlation structure was assumed.
We first fitted models that only included follow-up time and having received 
Results
Study Population
The study population consisted of 1444 out of 1845 eligible CCS, of whom 1403 (97.2%) underwent glomerular function testing ( Figure 1 ). Clinical characteristics of CCS are presented in Table 1 , Table 2 and Table 3 <0.001
Abbreviations: CNS, central nervous system; HD, high-dose; TBI, total body irradiation; yr, year. a: Childhood cancer survivors who died before first outpatient clinic visit, moved abroad, refused screening or lost to followup. 
Time Trends and Predictors of Glomerular Filtration RateMultivariable Linear Random Effects Model
In Figure 2 the patterns of predicted GFR over time for CCS treated with and without potentially nephrotoxic therapy are presented. GFR declined in both groups during follow-up (P<0.001). At 5 years after diagnosis the mean predicted GFR for CCS treated with and without potentially nephrotoxic therapy was 117.9 ml/min/1.73m 2 (95% CI, 116.0-119.9) and 133.6 ml/min/1.73m 2 (95% CI, 130.1-137.0), respectively. At 35 years after diagnosis the mean predicted GFR for CCS treated with and without potentially nephrotoxic therapy was 90.4 ml/min/1.73m 2 (95% CI, 86.9-93.9) and 98.3 ml/min/1.73m 2 (95% CI, 95.4-101.3), respectively. The differences in GFR between both groups were highly significant, as well as the differences in time trends (P<0.001).
As measured by the multivariable model, the predicted GFR deteriorated over time in all CCS (P<0.001). Figure 3 shows the predicted GFR time trends for the separate potentially nephrotoxic therapies. No significant interaction effects between time and cumulative ifosfamide, cisplatin, and carboplatin dose were demonstrated (P=0.33), meaning that there was no significant difference in predicted GFR time trend for CCS treated with low versus high cumulative doses of ifosfamide, cisplatin, and carboplatin. Therefore, we did not include these interactions in the prediction models. In Figure 4 the predicted GFR time trends for different cumulative doses of ifosfamide and cisplatin are presented.
Overall, ifosfamide was associated with a lower predicted GFR (P<0.001). An ifosfamide by time interaction was found (P=0.001), meaning that the pattern of predicted GFR over time was different for CCS treated with and without ifosfamide ( Figure 3, A) . The deterioration rate was higher in CCS treated without nephrotoxic therapy compared to CCS treated with ifosfamide, but only for the first 10 years of follow-up. Thereafter, CCS treated with ifosfamide experienced a further decline in predicted GFR, with a comparable deterioration rate as CCS treated without ifosfamide. As shown in Figure 4 , A-C, higher ifosfamide dose was also associated with a lower predicted GFR (P<0.001).
Cisplatin had a marginally significant overall effect on predicted GFR (P=0.029), which seems to be related to cumulative cisplatin dose (dose effect P=0.009), with higher dose related to a lower predicted GFR. carboplatin (Figure 3, C) . Thereafter, it seemed that the decline in predicted GFR stabilized. No significant effect of cumulative carboplatin dose was observed (P=0.82).
HD-methotrexate (P<0.001) and radiotherapy to the kidney region (P<0.001) had an effect on predicted GFR, whereas no significant effect of HD-cyclophosphamide was found (P=0.37). Marginally significant interactions were found with time for HD-methotrexate (P=0.014) and radiotherapy (P=0.018) (Figure 2 , D-F). Nephrectomy was associated with a lower predicted GFR (P<0.001). The predicted GFR time trend was different for CCS treated with and without nephrectomy, as demonstrated by the interaction with time (P<0.001) (Figure 3 , G). The deterioration rate was higher in CCS treated without nephrotoxic therapy compared to CCS treated with nephrectomy, but only within the first 15 years of follow-up. Thereafter, CCS treated with nephrectomy experienced a further decline in predicted GFR, with a comparable deterioration rate as CCS treated without nephrectomy. Also, older age at diagnosis was associated with a lower predicted GFR (P<0.001). An interaction effect between nephrectomy and age at diagnosis was demonstrated (P=0.006), meaning that the effect of nephrectomy on predicted GFR was different for CCS nephrectomized at an older age versus CCS nephrectomized at a younger age ( Figure 5 ).
No significant effect of sex was demonstrated (P=0.14).
Time Trends and Predictors of Glomerular DysfunctionMultivariable Logistic Regression Model
To confirm the clinical relevance of the results on continuous GFR we present the predicted time trends in glomerular dysfunction probability (GFR <90 ml/ min/1.73m
2 ) for CCS treated with and without potentially nephrotoxic therapy in Figure 6 . The glomerular dysfunction probability increased in both groups (P<0.001). At 5 years after diagnosis the mean predicted glomerular dysfunction probability for CCS treated with and without potentially nephrotoxic therapy was 12.4% (95% CI, 8.9-17.0) and 1.5% (95% CI, 0.3-7.9), respectively. At 35 years after diagnosis the mean predicted glomerular dysfunction probability for CCS treated with and without potentially nephrotoxic therapy was 36.5% (95% CI, 27.6-46.5) and 17.3% (95% CI, 12.0-24.2), respectively. These differences were highly significant, as well as the differences in time trends (P<0.001).
The glomerular dysfunction probability time trends for the separate potentially nephrotoxic therapies and for different cumulative doses of ifosfamide and cisplatin are shown in Figure 7 and Figure 8 . As in line with the results on continuous GFR, the time effects on glomerular dysfunction probability were highly significant (P<0.001). In addition, the analyses confirmed that ifosfamide (P<0.001), higher cumulative ifosfamide dose (P<0.001), cisplatin (P=0.002), higher cumulative cisplatin dose (P<0.001), and nephrectomy (P<0.001) were associated with a higher glomerular dysfunction probability ( Figure 7 , A, B, G and the effects of these treatments on glomerular dysfunction probability were not significantly different over time (Figure 7, A, C, E-G) . We did identify a cumulative cisplatin dose by time interaction (P=0.001), indicating that the pattern of glomerular dysfunction probability over time was different for CCS treated with lower and higher cisplatin doses. Again, this effect was most profound in CCS treated in the highest dose group (≥500 mg/m 2 ) (Figure 8, F) . 5  10  15  20  25  30  35 5  10  15  20  25  30  35 5  10  15  20  25  30  35 Time since childhood cancer diagnosis, years Glomerular dysfunction probability (95% CI)
Therapy:
Ifosfamide/Cisplatin No potentially nephrotoxic therapy Two studies investigated glomerular function in 63 CCS treated with cisplatin and/or carboplatin and 25 with ifosfamide 1 and 10 years after completion of treatment. 8, 9 Patients showed either recovery or deterioration in glomerular function, but the time trends were not significant. Two studies did also not demonstrate significant differences in GFR patterns in 23 CCS treated with carboplatin and 14 with cisplatin after 2 and 6 years, respectively, 12,15 while another study showed a significant recovery of GFR 4 years after end of treatment among 40 CCS treated with cisplatin. 19 The results of these studies must, however, be interpreted with caution, since sample sizes were small, follow-up was relatively short, and only few follow-up measurements were taken into account.
In the general population, the decline in glomerular function is a normal and expected phenomenon. The decline in creatinine clearance is a physiologic and pathologic consequence of aging. [25] [26] [27] A cross-sectional study among 174,448 subjects aged ≥18 years showed that the age-related decline amounts 8-11 ml/ min/1.73m 2 per 10 years. 26 As longitudinal population data on GFR is not available, we used CCS treated without potentially nephrotoxic therapy as an internal control group. Although this may have led to an underestimation of the effect sizes in the risk factor analyses (e.g. due to antibiotic treatment for neutropenia in the control group), we had the advantage that longitudinal data was available for both groups and that the GFR assessment method was identical. It is essential to realize that our population is still young (median age 26 years) and has a long life expectancy. As glomerular function continues to deteriorate, CCS will be at increased risk for premature chronic renal failure.
Thus far, no studies have evaluated predictors of glomerular function patterns over time in CCS. We showed that the time trend in predicted GFR is influenced by ifosfamide, carboplatin and nephrectomy in multivariable linear longitudinal analyses. Regarding CCS treated with ifosfamide and/or nephrectomy, it seems plausible that these patients experience an initial decline in glomerular function within the first five years after diagnosis. After a relatively stable period of ten years, the glomerular function starts to decline again, following the same pattern as CCS treated without nephrotoxic therapy. This latter decline is probably the result of aging. However, as we do not have longitudinal data on glomerular function within the normal population, we do not know if the age-related decline in childhood cancer survivors is worse than the decline in the general population.
Concerning CCS treated with carboplatin, the deterioration in glomerular function within the first ten years of follow-up is worse compared to survivors treated without nephrotoxic therapy. Thereafter, it seems that the decline stabilizes. This stabilization is most probably due to a loss of power however, as carboplatin is a relatively new chemotherapeutic agent. As a result, there are only a few longterm CCS treated with carboplatin just yet. Future studies have to confirm this stabilization after a longer follow-up duration.
Multivariable logistic longitudinal analyses showed that cisplatin dose was associated with a faster increase in glomerular dysfunction probability. Especially the highest cisplatin doses raise glomerular function abnormalities causing a GFR drop <90 ml/min/1.73m 2 .
As in line with our results, previous cross-sectional studies showed that ifosfamide, cisplatin, higher ifosfamide and cisplatin doses, and nephrectomy were associated with diminished GFR (7, 10, 11, 18) . In addition, we observed that carboplatin and HD-methotrexate were related with a lower GFR, but not with a GFR <90 ml/min/1.73m 2 . The effect of HD-methotrexate seems more a temporary than a long-term effect, since the association decreases over time.
HD-methotrexate is known to cause transient reductions in renal function, 28, 29 but the effects on late nephrotoxicity have been less intensively evaluated and results have been inconclusive. 13, 30 We observed that older age at diagnosis is associated with a decline in predicted GFR over time, especially in CCS treated with nephrectomy. Previous studies in
Wilms' tumour and neuroblastoma survivors did not find an influence of age at nephrectomy. [31] [32] [33] However, some other cross-sectional studies investigating nephrotoxicity of ifosfamide and platinum derivates did report correlations between predicted GFR and older age at treatment. 7, 8 A possible explanation for the effect of older age at diagnosis in nephrectomized CCS may be that a younger kidney can better cope with hyperfiltration after a nephrectomy than an older kidney.
In contrast to our expectations, we observed that CCS treated with radiotherapy had a higher GFR 15 years after diagnosis than CCS treated without nephrotoxic
therapy. An explanation for this finding may be the occurrence of hyperfiltration after radiotherapy. 34, 35 Also, muscle atrophy and malnutrition may affect creatinine levels of CCS treated with abdominal irradiation, which may lead to higher GFR estimations. We do not have precise radiation dose estimates received by the kidney region. It has been well-known that HD-radiation is detrimental for the kidneys, and therefore we always take radio-protective measures in order not to exceed the kidney dose limits. Future studies should perform detailed radiation dosimetry to evaluate the association between kidney radiation dose and glomerular function time trends.
Follow-up bias may have been present in this study as the frequency of followup visits for CCS with more severe health problems may be higher than for healthy CCS, which may have overestimated the results. In addition, the GEE approach assumes data to be missing completely at random. This means that it is assumed that the availability of measurements in an individual does not depend on the actual value of the outcome, conditionally on the co-variables in the model and that might not be true. However, we have no indication that CCS treated with nephrotoxic therapy and with an abnormal GFR had more frequent screening than other CCS. Moreover, it is likely that non-renal health problems were the main cause for variations in follow-up visit frequency. Therefore, the risk of follow-up bias in our study is limited. was the estimation method of preference for public health and general clinical practice usage when compared to the MDRD-formula. 37 Furthermore, a low GFR (<60 ml/min/1.93m 2 ) as calculated by estimation formulae was associated with all-cause and cardiovascular mortality in the general population in a large meta-analysis by Matsushita et al. 38 In conclusion, CCS treated with nephrotoxic therapy, especially ifosfamide, HD-cisplatin and nephrectomy, have a worse glomerular function compared to other CCS and this does not recover. We 
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